M&A Deal Summary

Acino Acquires Takeda Pharmaceutical - Primary Care Portfolio

On October 15, 2019, Acino acquired medical products company Takeda Pharmaceutical - Primary Care Portfolio from Takeda for 200M USD

Acquisition Highlights
  • This is Acino’s 1st transaction in the Medical Products sector.
  • This is Acino’s largest (disclosed) transaction.
  • This is Acino’s 1st transaction in Japan.

M&A Deal Summary
Date 2019-10-15
Target Takeda Pharmaceutical - Primary Care Portfolio
Sector Medical Products
Buyer(s) Acino
Sellers(s) Takeda
Deal Type Divestiture
Deal Value 200M USD

Target

Takeda Pharmaceutical - Primary Care Portfolio

Osaka, Japan
Takeda’s primary care portfolio includes pain management, gastroenterology, cardiovascular and respiratory and other 30 products.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Acino

Zurich, Czech Republic

website

Category Company
Founded 1836
Sector Life Science
Employees2,400
DESCRIPTION

Acino is a pharmaceutical company focused on developing, manufacturing and marketing well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino was founded in 1836 and is based in Zurich, Czech Republic.

DEAL STATS #
Overall 4 of 7
Sector (Medical Products) 1 of 2
Type (Divestiture) 3 of 5
Country (Japan) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-28 Litha Healthcare Group

Midrand, South Africa

Litha Healthcare Group Ltd. is a pharma group with around 160 employees providing products and services to public and private hospitals, pharmacies, general and specialist practitioners, as well as government law enforcement programs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-01 IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements

Saint Petersburg, Russia

IlmixGroup's Select Portfolio of Prescription Pharmaceutical Products and Food Supplements includes eight prescription pharmaceutical assets and food supplements in the areas of gynecology, gynecologic oncology, urology, and dermatology. The portfolio includes Indinol Forto, Cervicon-DIM, Indinol, Epigallate, Promisan, Indigal, and other clinical assets that are currently under development. These products are mainly used for the prevention and treatment of endometriosis, myoma, cervical dysplasia and prostate adenoma, and other disorders affecting the human reproductive system.

Buy -

Seller(S) 1

SELLER

Takeda

Tokyo, Japan

website

Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4,027.5B JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 3 of 6
Sector (Medical Products) 2 of 3
Type (Divestiture) 3 of 6
Country (Japan) 2 of 5
Year (2019) 2 of 2
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-09 Xiidra

Basel, Switzerland

XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease. Xiidra is based in Basel, Switzerland.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-26 PvP Biologics

San Diego, California, United States

PvP Biologics, Inc. is a developer of an oral enzyme for the treatment of celiac disease. PvP Biologics is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal